XML 78 R9.htm IDEA: XBRL DOCUMENT
v3.23.1

Segmentation of key figures | 12 Months Ended
--- | ---
Dec. 31, 2022
Disclosure of operating segments [abstract] |
Segmentation of key figures | 3. Segmentation of key figures 2022, 2021 and 2020 The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities. Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. The reporting segments are as follows: Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. Effective as of April 4, 2022, the Innovative Medicines Division is organized in two commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Prior to the announcement on April 4, 2022, the Innovative Medicines Division was organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net debt (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. • The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. • The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio. • The Operations unit, combines the Novartis Technical Operations (NTO) and Customer & Technology Solutions (CTS), following the internal reorganization announced on April 4, 2022. The Operations unit manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions, and delivers business support services across the Group, such as information technology, real estate and facility services and procurement. The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm’s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales to third parties, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities. Segmentation – consolidated income statements
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations)1 |  | Group |
(USD millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |
Net sales to third parties |  | 41 296 |  | 41 995 |  | 9 249 |  | 9 631 |  |  |  |  |  | 50 545 |  | 51 626 |
Sales to other segments |  | 825 |  | 795 |  | 205 |  | 180 |  | -1 030 |  | -975 |  |  |  |  |
Net sales |  | 42 121 |  | 42 790 |  | 9 454 |  | 9 811 |  | -1 030 |  | -975 |  | 50 545 |  | 51 626 |
Other revenues |  | 1 249 |  | 1 179 |  | 28 |  | 61 |  | 6 |  | 11 |  | 1 283 |  | 1 251 |
Cost of goods sold |  | -11 569 |  | -11 751 |  | -4 978 |  | -5 147 |  | 1 061 |  | 1 031 |  | -15 486 |  | -15 867 |
Gross profit |  | 31 801 |  | 32 218 |  | 4 504 |  | 4 725 |  | 37 |  | 67 |  | 36 342 |  | 37 010 |
Selling, general and administration |  | -11 679 |  | -12 306 |  | -2 062 |  | -2 062 |  | -512 |  | -518 |  | -14 253 |  | -14 886 |
Research and development |  | -9 172 |  | -8 641 |  | -824 |  | -899 |  |  |  |  |  | -9 996 |  | -9 540 |
Other income |  | 531 |  | 1 149 |  | 103 |  | 233 |  | 171 |  | 470 |  | 805 |  | 1 852 |
Other expense |  | -2 695 |  | -1 732 |  | -273 |  | -397 |  | -733 |  | -618 |  | -3 701 |  | -2 747 |
Operating income |  | 8 786 |  | 10 688 |  | 1 448 |  | 1 600 |  | -1 037 |  | -599 |  | 9 197 |  | 11 689 |
(Loss)/income from associated companies |  | -2 |  | 5 |  | 2 |  | 2 |  | -9 |  | 15 332 |  | -9 |  | 15 339 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  | -837 |  | -811 |
Other financial income and expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 20 |  | -80 |
Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 371 |  | 26 137 |
Income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | -1 416 |  | -2 119 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 955 |  | 24 018 |
Attributable to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders of Novartis AG |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 955 |  | 24 021 |
Non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | -3 |
Included in net income are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  | 379 |  | 71 |
Depreciation of property, plant and equipment |  | -837 |  | -859 |  | -204 |  | -210 |  | -122 |  | -139 |  | -1 163 |  | -1 208 |
Depreciation of right-of-use assets |  | -252 |  | -265 |  | -33 |  | -39 |  | -15 |  | -14 |  | -300 |  | -318 |
Amortization of intangible assets |  | -3 728 |  | -3 638 |  | -222 |  | -238 |  | -32 |  | -27 |  | -3 982 |  | -3 903 |
Impairment charges on property, plant and equipment, net |  | -407 |  | -271 |  |  |  | -9 |  |  |  | -1 |  | -407 |  | -281 |
Impairment of right-of-use assets |  | -3 |  |  |  |  |  |  |  |  |  |  |  | -3 |  |  |
Impairment charges on intangible assets, net |  | -1 299 |  | -367 |  | -25 |  | -28 |  | -2 |  | -8 |  | -1 326 |  | -403 |
Impairment charges and fair value changes on financial assets, net |  | -134 |  | 43 |  |  |  |  |  | -126 |  | -5 |  | -260 |  | 38 |
Additions to restructuring provisions |  | -1 069 |  | -240 |  | -40 |  | -62 |  | -259 |  | -26 |  | -1 368 |  | -328 |
Equity-based compensation of Novartis equity plans |  | -706 |  | -721 |  | -62 |  | -65 |  | -280 |  | -193 |  | -1 048 |  | -979 |
1 Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations)1 |  | Group |
(USD millions) |  | 2021 |  | 2020 |  | 2021 |  | 2020 |  | 2021 |  | 2020 |  | 2021 |  | 2020 |
Net sales to third parties |  | 41 995 |  | 39 013 |  | 9 631 |  | 9 646 |  |  |  |  |  | 51 626 |  | 48 659 |
Sales to other segments |  | 795 |  | 792 |  | 180 |  | 189 |  | -975 |  | -981 |  |  |  |  |
Net sales |  | 42 790 |  | 39 805 |  | 9 811 |  | 9 835 |  | -975 |  | -981 |  | 51 626 |  | 48 659 |
Other revenues |  | 1 179 |  | 1 018 |  | 61 |  | 53 |  | 11 |  | 168 |  | 1 251 |  | 1 239 |
Cost of goods sold |  | -11 751 |  | -10 927 |  | -5 147 |  | -5 252 |  | 1 031 |  | 1 058 |  | -15 867 |  | -15 121 |
Gross profit |  | 32 218 |  | 29 896 |  | 4 725 |  | 4 636 |  | 67 |  | 245 |  | 37 010 |  | 34 777 |
Selling, general and administration |  | -12 306 |  | -11 657 |  | -2 062 |  | -2 076 |  | -518 |  | -464 |  | -14 886 |  | -14 197 |
Research and development |  | -8 641 |  | -8 118 |  | -899 |  | -862 |  |  |  |  |  | -9 540 |  | -8 980 |
Other income |  | 1 149 |  | 922 |  | 233 |  | 176 |  | 470 |  | 644 |  | 1 852 |  | 1 742 |
Other expense |  | -1 732 |  | -1 871 |  | -397 |  | -831 |  | -618 |  | -488 |  | -2 747 |  | -3 190 |
Operating income |  | 10 688 |  | 9 172 |  | 1 600 |  | 1 043 |  | -599 |  | -63 |  | 11 689 |  | 10 152 |
Income from associated companies |  | 5 |  | 1 |  | 2 |  | 2 |  | 15 332 |  | 670 |  | 15 339 |  | 673 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  | -811 |  | -869 |
Other financial income and expense |  |  |  |  |  |  |  |  |  |  |  |  |  | -80 |  | -78 |
Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | 26 137 |  | 9 878 |
Income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | -2 119 |  | -1 807 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 018 |  | 8 071 |
Attributable to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders of Novartis AG |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 021 |  | 8 072 |
Non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | -3 |  | -1 |
Included in net income are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  | 71 |  | 91 |
Depreciation of property, plant and equipment |  | -859 |  | -912 |  | -210 |  | -282 |  | -139 |  | -124 |  | -1 208 |  | -1 318 |
Depreciation of right-of-use assets |  | -265 |  | -273 |  | -39 |  | -41 |  | -14 |  | -16 |  | -318 |  | -330 |
Amortization of intangible assets |  | -3 638 |  | -3 080 |  | -238 |  | -370 |  | -27 |  | -12 |  | -3 903 |  | -3 462 |
Impairment charges on property, plant and equipment, net |  | -271 |  | -324 |  | -9 |  | -116 |  | -1 |  |  |  | -281 |  | -440 |
Impairment charges on intangible assets, net |  | -367 |  | -768 |  | -28 |  | -141 |  | -8 |  | -5 |  | -403 |  | -914 |
Impairment charges and fair value changes on financial assets, net |  | 43 |  | 153 |  |  |  |  |  | -5 |  | 182 |  | 38 |  | 335 |
Additions to restructuring provisions |  | -240 |  | -217 |  | -62 |  | -98 |  | -26 |  | -39 |  | -328 |  | -354 |
Equity-based compensation of Novartis equity plans |  | -721 |  | -714 |  | -65 |  | -64 |  | -193 |  | -180 |  | -979 |  | -958 |
1 Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.
Segmentation – consolidated balance sheets
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations)1 |  | Group |
(USD millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |
Total assets |  | 75 510 |  | 79 220 |  | 16 078 |  | 16 192 |  | 25 865 |  | 36 383 |  | 117 453 |  | 131 795 |
Total liabilities |  | -16 966 |  | -15 929 |  | -3 710 |  | -3 632 |  | -37 354 |  | -44 412 |  | -58 030 |  | -63 973 |
Total equity |  |  |  |  |  |  |  |  |  |  |  |  |  | 59 423 |  | 67 822 |
Net debt 2 |  |  |  |  |  |  |  |  |  | 7 245 |  | 868 |  | 7 245 |  | 868 |
Net operating assets |  | 58 544 |  | 63 291 |  | 12 368 |  | 12 560 |  | -4 244 |  | -7 161 |  | 66 668 |  | 68 690 |
Included in assets and liabilities are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total property, plant and equipment |  | 8 488 |  | 9 168 |  | 1 861 |  | 1 901 |  | 415 |  | 476 |  | 10 764 |  | 11 545 |
Additions to property, plant and equipment 3 |  | 842 |  | 991 |  | 292 |  | 349 |  | 85 |  | 90 |  | 1 219 |  | 1 430 |
Total right-of-use assets |  | 1 233 |  | 1 349 |  | 90 |  | 104 |  | 108 |  | 108 |  | 1 431 |  | 1 561 |
Additions to right-of-use assets 3 |  | 196 |  | 222 |  | 31 |  | 26 |  | 20 |  | 73 |  | 247 |  | 321 |
Total goodwill and intangible assets |  | 51 357 |  | 53 919 |  | 9 230 |  | 9 603 |  | 358 |  | 255 |  | 60 945 |  | 63 777 |
Additions to goodwill and intangible assets 3 |  | 1 791 |  | 1 491 |  | 163 |  | 102 |  | 139 |  | 143 |  | 2 093 |  | 1 736 |
Total investment in associated companies |  | 107 |  | 170 |  | 9 |  | 7 |  | 27 |  | 28 |  | 143 |  | 205 |
Additions to investment in associated companies |  | 25 |  | 24 |  |  |  |  |  | 13 |  | 19 |  | 38 |  | 43 |
Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments |  |  |  |  |  |  |  |  |  | 18 930 |  | 28 329 |  | 18 930 |  | 28 329 |
Financial debts and derivative financial instruments |  |  |  |  |  |  |  |  |  | 26 175 |  | 29 197 |  | 26 175 |  | 29 197 |
Current income tax liabilities and deferred tax liabilities |  |  |  |  |  |  |  |  |  | 5 219 |  | 5 485 |  | 5 219 |  | 5 485 |
1 Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories
2 Note 29 provides additional disclosures related to net debt
3 Excluding the impact of business acquisitions
The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets for the years ended December 31, 2022 and 2021:
|  | Net sales to third parties1 |  | Total of selected non-current assets2 |
(USD millions) |  | 2022 |  | % |  | 2021 |  | % |  | 2020 |  | % |  | 2022 |  | % |  | 2021 |  | % |
Country |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Switzerland |  | 970 |  | 2 |  | 873 |  | 2 |  | 800 |  | 2 |  | 23 708 |  | 32 |  | 25 770 |  | 33 |
United States |  | 17 653 |  | 35 |  | 16 818 |  | 33 |  | 16 484 |  | 34 |  | 35 353 |  | 48 |  | 37 054 |  | 48 |
France |  | 2 257 |  | 4 |  | 2 522 |  | 5 |  | 2 442 |  | 5 |  | 3 188 |  | 4 |  | 3 615 |  | 5 |
Germany |  | 4 278 |  | 8 |  | 4 870 |  | 9 |  | 4 518 |  | 9 |  | 2 229 |  | 3 |  | 2 378 |  | 3 |
China |  | 3 128 |  | 6 |  | 3 052 |  | 6 |  | 2 573 |  | 5 |  | 599 |  | 1 |  | 703 |  | 1 |
Japan |  | 2 205 |  | 4 |  | 2 683 |  | 5 |  | 2 804 |  | 6 |  | 165 |  |  |  | 217 |  |  |
Other |  | 20 054 |  | 41 |  | 20 808 |  | 40 |  | 19 038 |  | 39 |  | 8 241 |  | 12 |  | 7 351 |  | 10 |
Group |  | 50 545 |  | 100 |  | 51 626 |  | 100 |  | 48 659 |  | 100 |  | 73 483 |  | 100 |  | 77 088 |  | 100 |
Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe |  | 18 467 |  | 37 |  | 20 197 |  | 39 |  | 18 715 |  | 38 |  | 35 896 |  | 49 |  | 37 525 |  | 49 |
Americas |  | 21 536 |  | 42 |  | 20 463 |  | 40 |  | 19 725 |  | 41 |  | 35 806 |  | 49 |  | 37 522 |  | 49 |
Asia/Africa/Australasia |  | 10 542 |  | 21 |  | 10 966 |  | 21 |  | 10 219 |  | 21 |  | 1 781 |  | 2 |  | 2 041 |  | 2 |
Group |  | 50 545 |  | 100 |  | 51 626 |  | 100 |  | 48 659 |  | 100 |  | 73 483 |  | 100 |  | 77 088 |  | 100 |
1 Net sales to third parties by location of customer
2 Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets
The Group’s largest, second-largest and third-largest customers account for approximately 16%, 11% and 7% of net sales to third parties, respectively (2021: 17%, 11% and 6%, respectively; 2020: 17%, 11% and 6%, respectively). All segments had sales to these customers in 2022, 2021 and 2020. The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 16%, 14% and 7%, respectively, of the trade receivables at December 31, 2022 (2021: 16%, 12% and 7%, respectively). Segmentation – net sales to third parties Net sales to third parties by region1
|  | 2022 USD m |  | 2021 USD m |  | Change (2021 to 2022) USD % |  | 2020 USD m |  | Change (2020 to 2021) USD % |
Innovative Medicines |  |  |  |  |  |  |  |  |  |  |
Europe |  | 13 554 |  | 14 919 |  | -9 |  | 13 484 |  | 11 |
US |  | 15 899 |  | 14 999 |  | 6 |  | 14 342 |  | 5 |
Asia/Africa/Australasia |  | 8 929 |  | 9 304 |  | -4 |  | 8 718 |  | 7 |
Canada and Latin America |  | 2 914 |  | 2 773 |  | 5 |  | 2 469 |  | 12 |
Total |  | 41 296 |  | 41 995 |  | -2 |  | 39 013 |  | 8 |
Of which in Established Markets |  | 30 548 |  | 31 459 |  | -3 |  | 29 643 |  | 6 |
Of which in Emerging Growth Markets |  | 10 748 |  | 10 536 |  | 2 |  | 9 370 |  | 12 |
Sandoz |  |  |  |  |  |  |  |  |  |  |
Europe |  | 4 913 |  | 5 278 |  | -7 |  | 5 231 |  | 1 |
US |  | 1 754 |  | 1 819 |  | -4 |  | 2 142 |  | -15 |
Asia/Africa/Australasia |  | 1 613 |  | 1 662 |  | -3 |  | 1 501 |  | 11 |
Canada and Latin America |  | 969 |  | 872 |  | 11 |  | 772 |  | 13 |
Total |  | 9 249 |  | 9 631 |  | -4 |  | 9 646 |  | 0 |
Of which in Established Markets |  | 6 460 |  | 6 855 |  | -6 |  | 7 089 |  | -3 |
Of which in Emerging Growth Markets |  | 2 789 |  | 2 776 |  | 0 |  | 2 557 |  | 9 |
Group |  |  |  |  |  |  |  |  |  |  |
Europe |  | 18 467 |  | 20 197 |  | -9 |  | 18 715 |  | 8 |
US |  | 17 653 |  | 16 818 |  | 5 |  | 16 484 |  | 2 |
Asia/Africa/Australasia |  | 10 542 |  | 10 966 |  | -4 |  | 10 219 |  | 7 |
Canada and Latin America |  | 3 883 |  | 3 645 |  | 7 |  | 3 241 |  | 12 |
Total |  | 50 545 |  | 51 626 |  | -2 |  | 48 659 |  | 6 |
Of which in Established Markets |  | 37 008 |  | 38 314 |  | -3 |  | 36 732 |  | 4 |
Of which in Emerging Growth Markets |  | 13 537 |  | 13 312 |  | 2 |  | 11 927 |  | 12 |
1 Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.
Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands
|  | 2022 USD m |  | 2021 USD m1 |  | Change (2021 to 2022) USD % |  | 2020 USD m1 |  | Change (2020 to 2021) USD % |
Cardiovascular |  |  |  |  |  |  |  |  |  |  |
Entresto |  | 4 644 |  | 3 548 |  | 31 |  | 2 497 |  | 42 |
Leqvio |  | 112 |  | 12 |  | nm |  |  |  | nm |
Total Cardiovascular |  | 4 756 |  | 3 560 |  | 34 |  | 2 497 |  | 43 |
Immunology |  |  |  |  |  |  |  |  |  |  |
Cosentyx |  | 4 788 |  | 4 718 |  | 1 |  | 3 995 |  | 18 |
Xolair 2 |  | 1 365 |  | 1 428 |  | -4 |  | 1 251 |  | 14 |
Ilaris |  | 1 133 |  | 1 059 |  | 7 |  | 873 |  | 21 |
Other |  | 1 |  |  |  | nm |  |  |  | nm |
Total Immunology |  | 7 287 |  | 7 205 |  | 1 |  | 6 119 |  | 18 |
Neuroscience |  |  |  |  |  |  |  |  |  |  |
Gilenya |  | 2 013 |  | 2 787 |  | -28 |  | 3 003 |  | -7 |
Zolgensma |  | 1 370 |  | 1 351 |  | 1 |  | 920 |  | 47 |
Kesimpta |  | 1 092 |  | 372 |  | 194 |  | 15 |  | nm |
Mayzent |  | 357 |  | 281 |  | 27 |  | 170 |  | 65 |
Aimovig |  | 218 |  | 215 |  | 1 |  | 164 |  | 31 |
Other |  | 1 |  | 1 |  | 0 |  |  |  | nm |
Total Neuroscience |  | 5 051 |  | 5 007 |  | 1 |  | 4 272 |  | 17 |
Solid Tumors |  |  |  |  |  |  |  |  |  |  |
Tafinlar + Mekinist |  | 1 770 |  | 1 693 |  | 5 |  | 1 542 |  | 10 |
Kisqali |  | 1 231 |  | 937 |  | 31 |  | 687 |  | 36 |
Votrient |  | 474 |  | 577 |  | -18 |  | 635 |  | -9 |
Lutathera |  | 471 |  | 475 |  | -1 |  | 445 |  | 7 |
Piqray |  | 373 |  | 329 |  | 13 |  | 320 |  | 3 |
Pluvicto |  | 271 |  |  |  | nm |  | 2 |  | nm |
Tabrecta |  | 133 |  | 90 |  | 48 |  | 35 |  | 157 |
Total Solid Tumors |  | 4 723 |  | 4 101 |  | 15 |  | 3 666 |  | 12 |
Hematology |  |  |  |  |  |  |  |  |  |  |
Promacta/Revolade |  | 2 088 |  | 2 016 |  | 4 |  | 1 738 |  | 16 |
Tasigna |  | 1 923 |  | 2 060 |  | -7 |  | 1 958 |  | 5 |
Jakavi |  | 1 561 |  | 1 595 |  | -2 |  | 1 339 |  | 19 |
Kymriah |  | 536 |  | 587 |  | -9 |  | 474 |  | 24 |
Adakveo |  | 194 |  | 164 |  | 18 |  | 105 |  | 56 |
Scemblix |  | 149 |  | 7 |  | nm |  |  |  | nm |
Other |  | 1 |  | 1 |  | 0 |  | 3 |  | -67 |
Total Hematology |  | 6 452 |  | 6 430 |  | 0 |  | 5 617 |  | 14 |
|  | 2022 USD m |  | 2021 USD m1 |  | Change (2021 to 2022) USD % |  | 2020 USD m1 |  | Change (2020 to 2021) USD % |
Other Promoted Brands |  |  |  |  |  |  |  |  |  |  |
Lucentis |  | 1 874 |  | 2 160 |  | -13 |  | 1 933 |  | 12 |
Xiidra |  | 487 |  | 468 |  | 4 |  | 376 |  | 24 |
Ultibro Group |  | 479 |  | 584 |  | -18 |  | 623 |  | -6 |
Beovu |  | 203 |  | 186 |  | 9 |  | 190 |  | -2 |
Other respiratory |  | 84 |  | 53 |  | 58 |  | 26 |  | 104 |
Total Other Promoted Brands |  | 3 127 |  | 3 451 |  | -9 |  | 3 148 |  | 10 |
Total Promoted Brands |  | 31 396 |  | 29 754 |  | 6 |  | 25 319 |  | 18 |
Established Brands |  |  |  |  |  |  |  |  |  |  |
Sandostatin |  | 1 238 |  | 1 413 |  | -12 |  | 1 439 |  | -2 |
Galvus Group |  | 859 |  | 1 092 |  | -21 |  | 1 199 |  | -9 |
Gleevec/Glivec |  | 745 |  | 1 024 |  | -27 |  | 1 188 |  | -14 |
Exforge Group |  | 743 |  | 901 |  | -18 |  | 980 |  | -8 |
Diovan Group |  | 652 |  | 773 |  | -16 |  | 1 003 |  | -23 |
Afinitor/Votubia |  | 512 |  | 938 |  | -45 |  | 1 083 |  | -13 |
Voltaren/Cataflam |  | 334 |  | 373 |  | -10 |  | 360 |  | 4 |
Zortress/Certican |  | 329 |  | 431 |  | -24 |  | 452 |  | -5 |
Exjade/Jadenu |  | 323 |  | 563 |  | -43 |  | 653 |  | -14 |
Neoral/Sandimmun(e) |  | 310 |  | 368 |  | -16 |  | 393 |  | -6 |
Contract manufacturing |  | 214 |  | 108 |  | 98 |  |  |  | nm |
Other |  | 3 641 |  | 4 257 |  | -14 |  | 4 944 |  | -14 |
Total Established Brands |  | 9 900 |  | 12 241 |  | -19 |  | 13 694 |  | -11 |
Total division net sales to third parties |  | 41 296 |  | 41 995 |  | -2 |  | 39 013 |  | 8 |
1 Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022
2 Net sales to third parties reflect Xolair sales for all indications.
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022
Brands |  | Brand classification by therapeutic area, other promoted brands or established brands |  | Key indications |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology |  | Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) |  | 2 770 |  | 2 018 |  | 4 788 |
Entresto |  | Cardiovascular |  | Chronic heart failure, hypertension |  | 2 354 |  | 2 290 |  | 4 644 |
Promacta/Revolade |  | Hematology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 1 083 |  | 1 005 |  | 2 088 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis (RMS) |  | 1 153 |  | 860 |  | 2 013 |
Tasigna |  | Hematology |  | Chronic myeloid leukemia (CML) |  | 877 |  | 1 046 |  | 1 923 |
Lucentis |  | Other Promoted Brands |  | Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) |  |  |  | 1 874 |  | 1 874 |
Tafinlar + Mekinist |  | Solid Tumors |  | BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication |  | 678 |  | 1 092 |  | 1 770 |
Jakavi |  | Hematology |  | Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) |  |  |  | 1 561 |  | 1 561 |
Zolgensma |  | Neuroscience |  | Spinal muscular atrophy (SMA) |  | 434 |  | 936 |  | 1 370 |
Xolair 1 |  | Immunology |  | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps |  |  |  | 1 365 |  | 1 365 |
Sandostatin |  | Established Brands |  | Carcinoid tumors, acromegaly |  | 800 |  | 438 |  | 1 238 |
Kisqali |  | Solid Tumors |  | HR+/HER2- metastatic breast cancer |  | 472 |  | 759 |  | 1 231 |
Ilaris |  | Immunology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) |  | 570 |  | 563 |  | 1 133 |
Kesimpta |  | Neuroscience |  | Relapsing-remitting multiple sclerosis (RRMS) |  | 921 |  | 171 |  | 1 092 |
Galvus Group |  | Established Brands |  | Type 2 diabetes |  |  |  | 859 |  | 859 |
Gleevec/Glivec |  | Established Brands |  | Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) |  | 205 |  | 540 |  | 745 |
Exforge Group |  | Established Brands |  | Hypertension |  | 14 |  | 729 |  | 743 |
Diovan Group |  | Established Brands |  | Hypertension |  | 55 |  | 597 |  | 652 |
Kymriah |  | Hematology |  | r/r pediatric and young adults acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) |  | 196 |  | 340 |  | 536 |
Afinitor/Votubia |  | Established Brands |  | Breast cancer/ tuberous sclerosis complex (TSC) |  | 171 |  | 341 |  | 512 |
Top 20 brands total |  |  |  |  |  | 12 753 |  | 19 384 |  | 32 137 |
Rest of portfolio |  |  |  |  |  | 3 146 |  | 6 013 |  | 9 159 |
Total division net sales to third parties |  |  |  |  |  | 15 899 |  | 25 397 |  | 41 296 |
1 Net sales to third parties reflect Xolair sales for all indications.
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021
Brands |  | Brand classification by therapeutic area, other promoted brands or established brands1 |  | Key indications |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology |  | Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) |  | 2 883 |  | 1 835 |  | 4 718 |
Entresto |  | Cardiovascular |  | Chronic heart failure |  | 1 712 |  | 1 836 |  | 3 548 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis (RMS) |  | 1 427 |  | 1 360 |  | 2 787 |
Lucentis |  | Other Promoted Brands |  | Age-related macular degeneration (AMD) |  |  |  | 2 160 |  | 2 160 |
Tasigna |  | Hematology |  | Chronic myeloid leukemia (CML) |  | 882 |  | 1 178 |  | 2 060 |
Promacta/Revolade |  | Hematology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 947 |  | 1 069 |  | 2 016 |
Tafinlar + Mekinist |  | Solid Tumors |  | BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC) |  | 606 |  | 1 087 |  | 1 693 |
Jakavi |  | Hematology |  | Myelofibrosis (MF), polycythemia vera (PV) |  |  |  | 1 595 |  | 1 595 |
Xolair 2 |  | Immunology |  | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps |  |  |  | 1 428 |  | 1 428 |
Sandostatin |  | Established Brands |  | Carcinoid tumors, acromegaly |  | 843 |  | 570 |  | 1 413 |
Zolgensma |  | Neuroscience |  | Spinal muscular atrophy (SMA) |  | 469 |  | 882 |  | 1 351 |
Galvus Group |  | Established Brands |  | Type 2 diabetes |  |  |  | 1 092 |  | 1 092 |
Ilaris |  | Immunology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) |  | 501 |  | 558 |  | 1 059 |
Gleevec/Glivec |  | Established Brands |  | Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) |  | 263 |  | 761 |  | 1 024 |
Afinitor/Votubia |  | Established Brands |  | Breast cancer/ tuberous sclerosis complex (TSC) |  | 521 |  | 417 |  | 938 |
Kisqali |  | Solid Tumors |  | HR+/HER2- metastatic breast cancer |  | 339 |  | 598 |  | 937 |
Exforge Group |  | Established Brands |  | Hypertension |  | 14 |  | 887 |  | 901 |
Diovan Group |  | Established Brands |  | Hypertension |  | 51 |  | 722 |  | 773 |
Kymriah |  | Hematology |  | r/r pediatric and young adults acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) |  | 230 |  | 357 |  | 587 |
Ultibro Group |  | Other Promoted Brands |  | Cronic obstructive pulmonary disease (COPD) |  |  |  | 584 |  | 584 |
Top 20 products total |  |  |  |  |  | 11 688 |  | 20 976 |  | 32 664 |
Rest of portfolio |  |  |  |  |  | 3 311 |  | 6 020 |  | 9 331 |
Total division net sales to third parties |  |  |  |  |  | 14 999 |  | 26 996 |  | 41 995 |
1 Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.
2 Net sales to third parties reflect Xolair sales for all indications.
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020
Brands |  | Brand classification by therapeutic area, other promoted brands or established brands1 |  | Key indications |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology |  | Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA) |  | 2 516 |  | 1 479 |  | 3 995 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis (RMS) |  | 1 562 |  | 1 441 |  | 3 003 |
Entresto |  | Cardiovascular |  | Chronic heart failure |  | 1 277 |  | 1 220 |  | 2 497 |
Tasigna |  | Hematology |  | Chronic myeloid leukemia (CML) |  | 859 |  | 1 099 |  | 1 958 |
Lucentis |  | Other Promoted Brands |  | Age-related macular degeneration (AMD) |  |  |  | 1 933 |  | 1 933 |
Promacta/Revolade |  | Hematology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 833 |  | 905 |  | 1 738 |
Tafinlar + Mekinist |  | Solid Tumors |  | BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC) |  | 569 |  | 973 |  | 1 542 |
Sandostatin |  | Established Brands |  | Carcinoid tumors, acromegaly |  | 837 |  | 602 |  | 1 439 |
Jakavi |  | Hematology |  | Myelofibrosis (MF), polycythemia vera (PV) |  |  |  | 1 339 |  | 1 339 |
Xolair 2 |  | Immunology |  | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU) |  |  |  | 1 251 |  | 1 251 |
Galvus Group |  | Established Brands |  | Type 2 diabetes |  |  |  | 1 199 |  | 1 199 |
Gleevec/Glivec |  | Established Brands |  | Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) |  | 315 |  | 873 |  | 1 188 |
Afinitor/Votubia |  | Established Brands |  | Breast cancer/ tuberous sclerosis complex (TSC) |  | 644 |  | 439 |  | 1 083 |
Diovan Group |  | Established Brands |  | Hypertension |  | 124 |  | 879 |  | 1 003 |
Exforge Group |  | Established Brands |  | Hypertension |  | 16 |  | 964 |  | 980 |
Zolgensma |  | Neuroscience |  | Spinal muscular atrophy (SMA) |  | 459 |  | 461 |  | 920 |
Ilaris |  | Immunology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD gout) |  | 400 |  | 473 |  | 873 |
Kisqali |  | Solid Tumors |  | HR+/HER2- metastatic breast cancer |  | 318 |  | 369 |  | 687 |
Exjade/Jadenu |  | Established Brands |  | Chronic iron overload |  | 138 |  | 515 |  | 653 |
Votrient |  | Solid Tumors |  | Renal cell carcinoma (RCC) |  | 259 |  | 376 |  | 635 |
Top 20 products total |  |  |  |  |  | 11 126 |  | 18 790 |  | 29 916 |
Rest of portfolio |  |  |  |  |  | 3 216 |  | 5 881 |  | 9 097 |
Total division net sales to third parties |  |  |  |  |  | 14 342 |  | 24 671 |  | 39 013 |
1 Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.
2 Net sales to third parties reflect Xolair sales for all indications.
Sandoz Division net sales to third parties by business franchise
|  | 2022 USD m |  | 2021 USD m |  | Change (2021 to 2022) USD % |  | 2020 USD m |  | Change (2020 to 2021) USD % |
Retail Generics 1 |  | 6 776 |  | 7 092 |  | -4 |  | 7 244 |  | -2 |
Biopharmaceuticals |  | 2 093 |  | 2 116 |  | -1 |  | 1 928 |  | 10 |
Anti-Infectives 1 |  | 380 |  | 423 |  | -10 |  | 474 |  | -11 |
Total division net sales to third parties |  | 9 249 |  | 9 631 |  | -4 |  | 9 646 |  | 0 |
1 Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.
The product portfolio of Sandoz is widely spread in 2022, 2021 and 2020. Segmentation – other revenue
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations) |  | Group |
(USD millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |
Profit-sharing income |  | 921 |  | 873 |  | 835 |  |  |  |  |  |  |  |  |  |  |  |  |  | 921 |  | 873 |  | 835 |
Royalty income |  | 28 |  | 74 |  | 107 |  | 18 |  | 24 |  | 25 |  | 6 |  | 11 |  | 168 |  | 52 |  | 109 |  | 300 |
Milestone income |  | 145 |  | 127 |  | 39 |  | 3 |  | 28 |  | 11 |  |  |  |  |  |  |  | 148 |  | 155 |  | 50 |
Other 1 |  | 155 |  | 105 |  | 37 |  | 7 |  | 9 |  | 17 |  |  |  |  |  |  |  | 162 |  | 114 |  | 54 |
Total other revenues |  | 1 249 |  | 1 179 |  | 1 018 |  | 28 |  | 61 |  | 53 |  | 6 |  | 11 |  | 168 |  | 1 283 |  | 1 251 |  | 1 239 |
1 Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration